OncoCyte (OCX) Short Interest Ratio & Short Volume → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free OCX Stock Alerts $2.94 -0.04 (-1.34%) (As of 01:42 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media OncoCyte Short Interest DataCurrent Short Volume178,300 sharesPrevious Short Volume177,600 sharesChange Vs. Previous Month+0.39%Dollar Volume Sold Short$531,334.00Short Interest Ratio / Days to Cover13.5Last Record DateMarch 15, 2024Outstanding Shares8,260,000 sharesFloat Size7,600,000 sharesShort Percent of Float2.35%Today's Trading Volume15,980 sharesAverage Trading Volume11,428 sharesToday's Volume Vs. Average140% Short Selling OncoCyte ? Sign up to receive the latest short interest report for OncoCyte and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatOCX Short Interest Over TimeOCX Days to Cover Over TimeOCX Percentage of Float Shorted Over Time Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. OncoCyte Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024178,300 shares $531,334.00 +0.4%2.4%13.5 $2.98 2/29/2024177,600 shares $516,816.00 -2.8%2.3%13.1 $2.91 2/15/2024182,800 shares $524,636.00 -1.5%2.4%14.3 $2.87 1/31/2024185,600 shares $575,360.00 -5.7%2.4%10.3 $3.10 1/15/2024196,800 shares $661,248.00 +8.3%2.6%10.6 $3.36 12/31/2023181,800 shares $454,500.00 -4.4%2.4%9.2 $2.50 Get the Latest News and Ratings for OCX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. 12/15/2023190,100 shares $589,310.00 -10.4%2.5%11.7 $3.10 11/30/2023212,200 shares $806,360.00 +4.7%2.8%14.4 $3.80 11/15/2023202,600 shares $802,296.00 -1.1%2.7%13.2 $3.96 10/31/2023204,800 shares $464,896.00 +8.4%2.7%15.8 $2.27 10/15/2023188,900 shares $612,980.50 +0.9%2.5%9.9 $3.25 9/30/2023187,200 shares $584,064.00 +0.7%2.5%10 $3.12 9/15/2023185,900 shares $593,021.00 +8.3%2.5%9.4 $3.19 8/31/2023171,600 shares $616,044.00 +3.5%2.3%8.2 $3.59 8/15/2023165,800 shares $553,772.00 +157.9%2.2%7.9 $3.34 7/31/202364,300 shares $268,131.00 +43.2%0.9%3.2 $4.17 7/15/202344,900 shares $195,135.40 -95.6%N/A3.5 $4.35 6/30/20231,020,000 shares $234,600.00 -4.7%N/A3.4 $0.23 6/15/20231,070,000 shares $230,050.00 -24.7%N/A3.2 $0.22 5/31/20231,420,000 shares $303,454.00 +22.4%N/A2.7 $0.21 5/15/20231,160,000 shares $308,560.00 -2.5%N/A2.3 $0.27 4/30/20231,190,000 shares $326,060.00 -14.4%N/A2.4 $0.27 4/15/20231,390,000 shares $443,688.00 +5.3%N/A2.8 $0.32 3/31/20231,320,000 shares $467,808.00 +6.5%N/A2.8 $0.35 3/15/20231,240,000 shares $248,000.00 +24.0%N/A2.7 $0.20 2/28/20231,000,000 shares $363,900.00 -4.8%N/A3.6 $0.36 2/15/20231,050,000 shares $471,975.00 -13.2%N/A3.6 $0.45 1/31/20231,210,000 shares $465,971.00 -14.2%N/A3.1 $0.39 1/15/20231,410,000 shares $688,080.00 -16.6%N/A3.4 $0.49 12/30/20221,690,000 shares $542,321.00 -14.7%N/A4.1 $0.32 12/15/20221,980,000 shares $792,000.00 -4.4%N/A5.1 $0.40 11/30/20222,070,000 shares $973,107.00 -12.7%N/A6.5 $0.47 11/15/20222,370,000 shares $967,908.00 -6.3%N/A6.1 $0.41 10/31/20222,530,000 shares $1.73 million -1.9%N/A7.9 $0.68 10/15/20222,580,000 shares $2.00 million -1.5%N/A9.1 $0.78 9/30/20222,620,000 shares $1.91 million +5.7%N/A8.8 $0.73 9/15/20222,480,000 shares $2.23 million -8.2%N/A5.6 $0.90 8/31/20222,700,000 shares $2.13 million No ChangeN/A5.5 $0.79 7/30/20213,040,000 shares $0.00 -3.8%3.6%6.9 $0.00 7/15/20213,160,000 shares $0.00 +2.6%3.6%6.9 $0.00AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. OCX Short Interest - Frequently Asked Questions What is OncoCyte's current short interest? Short interest is the volume of OncoCyte shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 178,300 shares of OCX short. 2.35% of OncoCyte's shares are currently sold short. Learn More on OncoCyte's current short interest. What is a good short interest ratio for OncoCyte? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OCX shares currently have a short interest ratio of 14.0. Learn More on OncoCyte's short interest ratio. Which institutional investors are shorting OncoCyte? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of OncoCyte: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for OncoCyte? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.35% of OncoCyte's floating shares are currently sold short. Is OncoCyte's short interest increasing or decreasing? OncoCyte saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 178,300 shares, an increase of 0.4% from the previous total of 177,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is OncoCyte's float size? OncoCyte currently has issued a total of 8,260,000 shares. Some of OncoCyte's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. OncoCyte currently has a public float of 7,600,000 shares. How does OncoCyte's short interest compare to its competitors? 2.35% of OncoCyte's shares are currently sold short. Here is how the short interest of companies compare to OncoCyte: ARCA biopharma, Inc. (1.28%), Cardio Diagnostics Holdings, Inc. (2.73%), Trinity Biotech plc (0.06%), Biomerica, Inc. (0.46%), Aspira Women's Health Inc. (2.94%), DURECT Co. (3.72%), ImmuCell Co. (0.12%), Achilles Therapeutics plc (0.18%), InflaRx (0.71%), Achieve Life Sciences, Inc. (3.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short OncoCyte stock? Short selling OCX is an investing strategy that aims to generate trading profit from OncoCyte as its price is falling. OCX shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against OncoCyte? A short squeeze for OncoCyte occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OCX, which in turn drives the price of the stock up even further. How often is OncoCyte's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ABIO Short Interest Data CDIO Short Interest Data TRIB Short Interest Data BMRA Short Interest Data AWH Short Interest Data DRRX Short Interest Data ICCC Short Interest Data ACHL Short Interest Data IFRX Short Interest Data ACHV Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OCX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy